Comparative Pharmacology
Head-to-head clinical analysis: NITROL versus NITRONAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROL versus NITRONAL.
NITROL vs NITRONAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NITROL (nitroglycerin) is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase and increases cyclic guanosine monophosphate (cGMP) levels, leading to vasodilation.
Nitronal (nitroglycerin) is a vasodilator that works by releasing nitric oxide, which activates guanylate cyclase and increases cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, leading to relaxation and dilation of peripheral arteries and veins, predominantly venous dilation.
Sublingual: 0.3-0.6 mg every 5 minutes as needed for angina, up to 3 doses in 15 minutes. Translingual spray: 1-2 sprays (0.4 mg/spray) under tongue every 5 minutes as needed, max 3 doses in 15 minutes. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours. Intravenous: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes until response, usual range 10-200 mcg/min.
Initial intravenous infusion of 5 mcg/min, titrated by 5 mcg/min every 3-5 minutes to clinical effect; typical maintenance 10-200 mcg/min.
None Documented
None Documented
1-4 minutes for nitroglycerin; clinical effect disappears within 30-60 minutes due to rapid metabolism and redistribution.
Terminal elimination half-life is 1-4 minutes (due to rapid hepatic metabolism via glutathione S-transferase). Clinical context: necessitates continuous IV infusion for sustained effect.
Renal: minimal, <1% unchanged; extensive metabolism by liver, metabolites excreted renally. Biliary/fecal: negligible.
Renal: ~60% as inactive metabolites; fecal: ~35% via bile; unchanged drug: <1%.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator